AgingResearch.NewsJoin free

HanAll BioPharma

CompanySouth Korea

HanAll BioPharma develops 3 assets, the furthest approved (dutasteride in androgenetic alopecia). Mostly small molecule acting on SRD5A2, SRD5A1 and KCNJ8; based in South Korea.

3
Assets
Furthest stage
Approved
4
Trials
1
Signal

Pipeline

3

  • dutasteride

    Inhibits type 1 and type 2 5-alpha-reductase, reducing dihydrotestosterone production.

    Approved, Small molecule, SRD5A1, SRD5A2, androgenetic alopecia

  • finasteride

    Inhibits 5-alpha-reductase, reducing dihydrotestosterone production and prostate enlargement.

    Approved, Small molecule, SRD5A2, androgenetic alopecia, male pattern baldness

  • minoxidil

    Opens potassium channels and promotes hair follicle growth.

    Approved, Small molecule, KCNJ8, female pattern hair loss, hair loss

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms6
  • Trials4
  • Signals1
  • Similar companies6

Intelligence